Apremilast

• Randomized double blind controlled trial comparing the safety and efficacy of apremilast versus placebo in severe forms of recurrent aphthou… Pending
  2024-514659-13-00 Phase III 1 country Centre Hospitalier Universitaire Rouen
• EBUL0. A 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 years of age with Epidermolysis bul… Recruiting
  2023-508794-83-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
• Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting
  2023-503435-17-00 Phase III 12 countries Amgen Inc.
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• Phase 3, Open-label Apremilast Pediatric Long-term Extension Study in Children with Oral Ulcers Associated With Behçet’s Disease or Juvenile… Recruiting
  2023-503433-21-00 Phase III 3 countries Amgen Inc.
• Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended
  2023-503436-40-00 Phase III 4 countries Amgen Inc.
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended
  2023-506257-37-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended
  2023-508959-39-00 Phase III 9 countries Alumis Inc.
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended
  2023-507193-40-00 Phase III 6 countries Alumis Inc.
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended
  2023-505842-24-00 Phase III 9 countries Takeda Development Center Americas Inc.
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended
  2023-505841-22-00 Phase III 3 countries Takeda Development Center Americas Inc.

Showing 1–11 of 11 trials